FDA approves UroGen’s Zusduri for non-muscle invasive bladder cancer

The Food and Drug Administration said approved UroGen Pharma’s (URGN) Zusduri for adult patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. The agency pointed out that serious adverse reactions occurred in 12% of patients, including urinary retention and urethral stenosis. A fatal adverse reaction of cardiac failure occurred in one patient.